Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
Extends IP protection of TG02 in the US until 09.12.2034Oslo, 3 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the US Patent and Trademark Office has granted US Patent no 9,775,892, Peptide mixture. The patent protects the composition of Targovax' mutant-RAS specific neoantigen vaccine TG02, for stimulating the immune system of cancer patients with RAS mutated tumors. Targovax' proprietary mutant-RAS neoantigen vaccine platform is designed to treat